Novabay Pharmaceuticals Inc IPO year
What is the IPO year of Novabay Pharmaceuticals Inc?
The IPO year of Novabay Pharmaceuticals Inc is 2007
What is the definition of IPO year?
Initial public offering is a type of public offering in which shares of a company usually are sold to institutional investors that in turn, sell to the general public, on a securities exchange, for the first time.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO year of companies in the Health Care sector on NYSEMKT compared to Novabay Pharmaceuticals Inc
What does Novabay Pharmaceuticals Inc do?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Companies with ipo year similar to Novabay Pharmaceuticals Inc
- G3 Exploration has IPO year of 2006
- Evolis SA has IPO year of 2006
- Unity Infraprojects has IPO year of 2006
- News Invest has IPO year of 2006
- AuStar Gold has IPO year of 2006
- Sky and Space Global has IPO year of 2006
- Novabay Pharmaceuticals Inc has IPO year of 2007
- Manas Resources has IPO year of 2008
- Mastech Digital Inc has IPO year of 2008
- MYR Inc has IPO year of 2008
- Dana Inc has IPO year of 2008
- American Water Works Co has IPO year of 2008
- Chromadex Corp has IPO year of 2008